Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067600 | 1.00 | CCR2 (0.69) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL700800 | 0.87 | ALDH1A1 (0.69) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL30044340 | 0.85 | CCR2 (0.58) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL14259845 | 0.85 | CCR2 (0.50) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL13738783 | 0.85 | CCR2 (0.58) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL7463101 | 0.84 | CCR2 (0.71) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL10757133 | 0.84 | ALDH1A1 (0.66) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL6682164 | 0.83 | ALDH1A1 (0.64) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL13701158 | 0.83 | CCR2 (0.69) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL13305894 | 0.83 | CCR2 (0.69) | CCR2ALDH1A1CYP1A2POLBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | disclosed |
| CN-117616011-A | Inhibitors of transglutaminase | 策迪拉有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117561240-A | Inhibitors of transglutaminase | 策迪拉有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
| US-6214856-B1 | TREATING NEURODEGENERATIVE DISORDERS, E.G., ALZHEIMER'S DISEASE, STROKES, TRAUMATIC BRAIN INJURY; ANTIISCHEMIC AGENTS; MUSCULAR DYSTROPHY; ALSO CATARACTS; PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |
| EP-1018878-A4 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORP (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1018878-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SmithKline Beecham Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998041092-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-24 | — | — | WO | disclosed |
| US-5523411-A | Synthesis of mitomycin and its analogs | RUTGERS UNIVERSITY (US) | 1996-06-04 | — | — | US | disclosed |
| US-4697018-A | CARBONLESS DUPLICATION OR THERMAL MARKING DYES | THE HILTON-DAVIS CHEMICAL CO. (US) | 1987-09-29 | — | — | US | disclosed |
| US-4558137-A | CHROMAGENS, PRESSURE AND HEAT SENSITIVE CARBONLESS DUPLICATING SYSTEMS | THE HILTON-DAVIS CHEMICAL CO. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4403791-A | Carbonless duplicating and marking systems | STERLING DRUG INC. (US) | 1983-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | CCR2 1942/4885ALDH1A1 3864/4885CYP1A2 1346/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CCR2 4801/4885ALDH1A1 1825/4885CYP1A2 714/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CCR2 4801/4885ALDH1A1 1825/4885CYP1A2 714/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CCR2 4801/4885ALDH1A1 1825/4885CYP1A2 714/4885 |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CCR2 4801/4885ALDH1A1 1825/4885CYP1A2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.